ChemoMetec A/S/DKr CHEMM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ChemoMetec A/S
ChemoMetec A/S is a biotechnology and life sciences company that specializes in the development, production, and sale of high-quality instruments for cell counting and analysis. Located in Denmark, the company serves various sectors, including research institutions, academic laboratories, and pharmaceutical companies. Its product portfolio includes advanced cell counters and analyzers, such as the NucleoCounter series, which are utilized for precise and reliable cell counting across multiple applications. Established in 1997, ChemoMetec has positioned itself through innovative technology that focuses on accuracy and ease of use. The company operates with a global reach, serving customers through both direct sales and a network of distributors.
- Ticker
- DKr CHEMM
- Sector
- Health
- Primary listing
- CSE
- Employees
- 174
- Headquarters
- Allerød, Denmark
- Website
- chemometec.com
ChemoMetec A/S Metrics
BasicAdvanced
kr 11B
52.67
kr 11.60
1.39
-
Price and volume
Market cap
kr 11B
Beta
1.39
52-week high
kr 803.00
52-week low
kr 235.20
Average daily volume
50K
Financial strength
Current ratio
4.092
Quick ratio
3.063
Long term debt to equity
0.003
Total debt to equity
0.006
Dividend payout ratio (TTM)
60.35%
Interest coverage (TTM)
641.93%
Profitability
EBITDA (TTM)
265.877
Gross margin (TTM)
95.10%
Net profit margin (TTM)
39.49%
Operating margin (TTM)
49.11%
Effective tax rate (TTM)
21.82%
Revenue per employee (TTM)
kr 2,940,000
Management effectiveness
Return on assets (TTM)
18.45%
Return on equity (TTM)
28.56%
Valuation
Price to earnings (TTM)
52.672
Price to revenue (TTM)
20.8
Price to book
14.57
Price to tangible book (TTM)
20.43
Price to free cash flow (TTM)
93.285
Free cash flow yield (TTM)
1.07%
Free cash flow per share (TTM)
6.55
Growth
Revenue change (TTM)
3.12%
Earnings per share change (TTM)
15.55%
3-year revenue growth (CAGR)
4.77%
10-year revenue growth (CAGR)
19.62%
3-year earnings per share growth (CAGR)
4.15%
10-year earnings per share growth (CAGR)
33.02%
Bulls say / Bears say
Higher-than-expected demand for NC-203 and a lower cost base led ChemoMetec to raise FY2026/27 revenue guidance to DKK560–590 million and EBITDA guidance to DKK330–345 million. The upgrade points to stronger momentum in its new instrument cycle. (ChemoMetec)
The Roche collaboration gives ChemoMetec a route into bioprocessing customers beyond its established markets, using jointly marketed cell counters and analysers. If the partnership converts into orders, it could widen the company’s commercial reach. (MedWatch)
ChemoMetec is developing automation and software alongside its instruments, including XM Octopus and the XM50, for cell and gene therapy and bioprocessing workflows. Adoption could broaden the company’s offering beyond standalone cell counters. (GlobeNewswire)
FY2025/26 revenue grew only 3%, while consumables sales fell 4%; revenue in the US and Canada, its largest region, declined 6% in Danish kroner. This shows that core customer activity remains uneven despite recent instrument demand. (Nasdaq Copenhagen)
The Roche, Tecan and Hamilton collaborations are not included in guidance because ChemoMetec has not received firm orders, and management says customer validations can take years. Delays would defer a material part of the partnership growth opportunity. (Investing.com)
A September valuation review put the shares at 42.3 times earnings after a sharp recent rise and said they traded above its discounted-cash-flow estimate. That premium leaves less room for slower growth or execution setbacks before investors reassess the shares. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2026.
Upcoming events
No upcoming events
Funds containing ChemoMetec A/S
AllUSDEURGBP
Fund name | Fund size | DKr CHEMM weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.16% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.16% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.16% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.09% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.